There’s been a shift in the acceptance of real-world data (RWD) and real-world evidence (RWE) in regulatory decision-making. What was once considered merely anecdotal is now deemed reliable. Between the FDA’s final 2017 guidance, the RWE Framework document from 2018 and the April 2021 report on RWE-based decisions, the agency is showing its increasing emphasis on real-world information.
FDA regulatory experts Kristin Zielinski Duggan, Lynn Mehler and Sally Gu will dig into the FDA’s guidance around RWE as support for regulatory decision-making and detail key examples of how this evidence has been used. They will discuss the limitations of these approaches and the steps you can take to ensure the validity and usefulness of your data.
- FDA Guidance and Documentation
- Understanding the FDA’s guidance document on the use of RWE to support regulatory decision-making for medical devices and pharmaceuticals
- Analyzing the FDA’s framework for the RWE program
- Exploring illustrative examples of RWE used in medical device and pharmaceutical regulatory decisions
- Practicalities of Relying on RWD/RWE
- The limitations of turning to RWD and RWE
- Steps to successfully use RWD and RWE
- Premarket and Postmarket Obligations
- Using RWD and RWE for premarket and postmarket obligations
The FDA is shifting its acceptance of real-world data and evidence. If you’re planning on relying on RWD and RWE, you’ll need to understand these changes. Stay ahead of the curve and determine the best path forward.
Who Will Benefit:
- Medical device companies
- Pharmaceutical companies
- Groups considering reliance on RWD/RWE
- Management teams
- Research and development staff
- Regulatory affairs professionals
- Quality professionals